Basics of Biotech is a comprehensive, two-day course meant to provide you with an overview of the development of biopharmaceuticals.  The course will start with foundational basics and give a detailed overview of the entire process from discovery to commercialization.  As an attendee, you will learn a bit of the science behind biotech products, the clinical research process, regulatory filings, and scale-up for manufacturing.  Different types of products such as biologic drugs, biosimilars, personalized medicine, stem cell, and regenerative medicine will be outlined.

This training will progress under the umbrella of the development timeline, from start to finish.

Learning Objectives:

Over two days, this interactive course will…

• Explain the biotech processes, what they are and how they work
• Explain the biotech lab, what it looks like and how it operates
• Explain the biotech product development process
• Examine how manufacturing facilities are built and operate
• Examine the evolution of biotech manufacturing
• Relate each step to the previous steps, and provide you with a seamless, consistent overview
• Provide you with an overview of basic science, terminology, and common areas of failure in product development
• Prepare you to improve in your current role, or be ready to enter the biotech field with some foundational knowledge

Who Should Attend?

This course will benefit anyone who is new to the biotech/biopharma industries, needs to know the process at a high-level, or those who need a refresher.  There is no level of prerequisite knowledge or understanding necessary to attend.  Additionally, this course will be of value to those who support any step within the development process, including outside vendors.

Leading industry players will discuss…

• A med tech company’s experience with Pennsylvania specific grants and tax incentives
• Approaches to securing SBIR & STTR funding
• FREE education and guidance opportunities to help win grants
• Other funding opportunities

Date: Thursday, December 12, 2019
Location: Hofbräuhaus Pittsburgh – Southside Works 2705 South Water St Pittsburgh, Pa 15203
Timing: 11:30 – 1:30 PM

Panelists:
Michael Emery, Chief Financial Officer, Tyber Medical
Jim Fendrick, President and CEO, Rockland Immunochemicals
Kelly Wylam, Director, Innovation Partnership

Panelists Bios:
Michael Emery, Chief Financial Officer, Tyber Medical

Mr. Emery, Chief Financial Officer, Tyber Medical, has over 25 years’ experience in Accounting, Finance, Business Systems, Acquisition Integration, and Process Improvement. Before joining Tyber Medical, Mr. Emery served as Global Vice President of Finance & Accounting at Plasma Surgical. At Plasma Surgical he was responsible for all Finance, Accounting, Information Systems and Legal functions for multiple legal entities across the globe, including the United States, United Kingdom, France, and BVI. He has also served on the Boards of  United Kingdom and French entities. Prior to Plasma Surgical, he was the Corporate Controller for Solvay Pharmaceuticals, a $1B revenue entity.

Jim Fendrick, President & CEO, Rockland Immunochemicals

Jim Fendrick, a 30-year veteran of the biotechnology industry, is President and CEO of Rockland Immunochemicals, Inc. and chairman of its Board of Directors.
A global biotechnology company focusing on life science research tools and contract research, Rockland is a leading expert in antibodies and partners with major government, academic and biopharma institutions throughout the world.  Rockland also invests in biotechnology companies that address unmet medical needs.
Jim is an active board member for the Jefferson Institute for Bioprocessing (JIB), the Montgomery County Development Corporation (MCDC), and a founding member of PHL Art & Life Science (PALS) Initiative. He has partnered professionally and personally with Life Sciences Pennsylvania (LSPA) and the Yellow Springs Art Show.  A graduate of Gettysburg College, Jim and his wife, Maureen, reside in Chester County, PA.

Kelly Wylam, Director, Innovation Partnership 

Ms. Wylam has over 25 years of experience with a variety of businesses and economic development programs in PA.  In her current position with the BFTP Network, Ms. Wylam Directs the Innovation Partnership (IPart), PA’s premiere SBIR/ STTR statewide assistance program, providing clients with counseling and supports the IPart’s network of member organizations throughout the Commonwealth.  She is seasoned in grant proposal preparation, funding acquisition and financial administration.  In her previous capacity with DCED’s Office of Technology Investment, Ms. Wylam managed the Commonwealth’s Pennsylvania Initiative for Nanotechnology (PIN), provided oversight for the BFTDA’s University Grant Funding and Keystone Innovation Starter Kit (KISK) programs, and worked with technology-oriented businesses seeking funding. Ms. Wylam has also worked at DCED in the business financing area managing pooled bond financings, and small business lending and grant programs.  She has a BS in PR/Communications from Millersville University and an MA in Government from Lehigh University.

Sponsorships are available: If you are interested in sponsorship, please contact Melissa Callum, Director, Programs, at mcallum@lifesciencespa.org or 610-947-6800 ext 208

Life Sciences Pennsylvania launched a series called “Connect@” for members to network in a casual and relaxed atmosphere. Please join us for the opportunity to reconnect with life sciences colleagues from the region as well as to meet newcomers to the community.

*Although the event is complimentary you must register to attend.

When: January 29, 2020
Where: Woodview Way, Malvern, PA 19355
Time: 4:30PM – 6:30PM

Click here to learn more about Ave – Malvern!

AVE Flexible-Stay Furnished Apartments & Luxury Apartments

Live better! AVE’s seven convenient locations in the Greater Philadelphia Area offer 1, 2 & 3 bedroom flexible-stay, fully furnished apartments that are perfect for individuals who are relocating, renovating, in between homes, or traveling on extended business. They also offer luxury apartments for discerning renters who desire carefree living year-round. Experience high-touch service from professional team members on site 7 days a week and unparalleled, on-demand amenities including resort pools, flex workspaces, state-of-the-art fitness centers, wellness classes, resident events, and more. Visit www.aveliving.com or call 267-400-1963.

*This event is postponed from December 3, 2019*

Hear from the CEO of a pharma company working on synthetic cannabinoids, an investor actively seeking new investments in the legal cannabis market, and a pediatric neurologist managing clinical trials at CHOP, testing the efficacy of a cannabis extract for treating severe childhood epilepsy.  Attendees can enjoy the benefit of a Q+A interactive panel, breakfast, and networking with industry leaders.

Agenda

7:15 a.m. – 8:15 a.m.     Registration & Networking
8:15 a.m. – 9:30 a.m.     Panel Discussion

Speakers:

Armando Anido, Chairman and CEO, Zynerba Pharmaceuticals, Inc.

Armando Anido has served as our Chairman and Chief Executive Officer (CEO) since October 2014. Mr. Anido has more than 30 years of executive, operational and commercial leadership experience in the biopharmaceutical industry, particularly in leading CNS transdermal patch and gel products through the entire product life cycle. Prior to Zynerba, Mr. Anido served as CEO of two publicly traded companies. Most recently, he was the CEO of NuPathe (NASDAQ: PATH), which was acquired by Teva Pharmaceuticals in February 2014. At NuPathe, he led the company through FDA approval of its lead product, Zecuity®, the first transdermal patch for migraine, to pre-launch before successfully selling the company to Teva. He also served as President and CEO of Auxilium Pharmaceuticals (NASDAQ: AUXL), where under his leadership, sales grew from $42 million in 2005 to more than $260 million in 2011 and market capitalization increased from $200 million to more than $900 million. Prior to Auxilium, Mr. Anido served as Executive Vice President, Sales and Marketing, at MedImmune and prior to that, in senior sales and marketing positions at GlaxoWellcome and Lederle Laboratories. At GlaxoWellcome, he was Vice President, Central Nervous System Marketing, responsible for the commercialization of the epilepsy, migraine and depression businesses in the U.S. He is currently a member of the Board of Directors of Life Sciences Pennsylvania, and he was a member of the Board of Directors of Adolor until it was sold to Cubist in December 2011. Mr. Anido earned a BS in Pharmacy and an MBA from West Virginia University.

Howard Goodwin, M.D., Partner, Intrinsic Capital Partners

For the last 18 years, Dr. Goodwin has demonstrated a proven acumen investing in healthcare businesses at top investment firms, including Maverick Capital, Citadel Investments and, most recently, as a portfolio manager at Millennium Partners.  Dr. Goodwin began his investment career at Graham Partners, a middle-market private equity firm.  Prior to beginning his investment career, Dr. Goodwin received his medical degree from Thomas Jefferson University.

Intrinsic Capital Partners is an investment firm focused on life-science and technology businesses within the legal cannabis market. The Intrinsic team brings institutional investment discipline and world-class operating experience to build and scale industry-leading companies that address unmet needs across the supply chain.

Eric Marsh M.D., Ph.D., Associate Professor of Neurology and Pediatrics, Division of Neurology, Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania 

Dr. Marsh is a child neurologist at CHOP.  His clinical work centers around diagnosing and treating children with early onset epilepsy, brain malformations, and intellectual disabilities.  He is the director of the neurogenetics clinic.  His’s research program focuses on understanding how changes in brain development lead to epilepsy, intellectual disability, and autism. He combines molecular and physiological tools in mouse models to ask questions about the interaction of normal development with single gene mutations to determine how the brain responds to perturbations in development.  He has been involved, since the beginning of compassionate use and clinical trials with GW Pharma on Epidiolex, the purified CBD used for the treatment of intractable seizures.

The 2020 Annual Dinner is the premier event of the season for the life sciences industry in Pennsylvania. On March 19, 2020 more than 1,400 attendees will convene for this can’t-miss event.  We look forward to hosting industry and community leaders for an evening spent celebrating the successes of the past year.

Sponsorship Opportunities are available. For any additional questions or information, please contact Melissa Callum at mcallum@lifesciencespa.org.

*Following your purchase, you will receive an email confirming your purchase and steps on how to send over your table attendees.

CANCELLATION POLICY: Table purchases are non-refundable.  For Individual Tickets, please contact LSPA to request a refund.  As of COB Friday February 28, 2020 LSPA will no longer refund ticket purchases.